华熙的玻尿酸王者地位,正在被胶原蛋白反攻

华尔街见闻
12 Apr

曾几何时,市场还在讨论重组胶原蛋白何时复刻玻尿酸神话,在护肤品乃至医美行业占有一席之地。 如今,玻尿酸龙头华熙生物(688363.SH)和重组胶原蛋白龙头企业巨子生物(2367.HK)的业绩反差,似乎进一步验证了先前预期。 2024年,华熙生物的收入、归母净利润分别为53.71亿元、1.74亿元,分别同比下滑了11.61%、71.10%。 同期巨子生物的收入、净利润分别达到55.39亿元、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10